Book contents
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Chapter 1 Introduction
- Chapter 2 What Are Club Drugs and NPS and Why Are They Important?
- Chapter 3 A Brief History of NPS Production and Distribution
- Chapter 4 Classification Framework for Club Drugs and NPS
- Chapter 5 The Clinical Challenge of Club Drugs and NPS
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Chapter 3 - A Brief History of NPS Production and Distribution
from Part I - Introduction
Published online by Cambridge University Press: 21 September 2020
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Chapter 1 Introduction
- Chapter 2 What Are Club Drugs and NPS and Why Are They Important?
- Chapter 3 A Brief History of NPS Production and Distribution
- Chapter 4 Classification Framework for Club Drugs and NPS
- Chapter 5 The Clinical Challenge of Club Drugs and NPS
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Summary
New psychoactive substances began to cause concern around 2008 when a number of new and diverse drugs were detected on global drug markets. The initial aim of these new drugs appeared to be to mimic the psychoactive effect of established illicit drugs such as MDMA and cocaine, while avoiding legal sanctions to enable their sale by high street vendors.
- Type
- Chapter
- Information
- Club Drugs and Novel Psychoactive SubstancesThe Clinician's Handbook, pp. 5 - 10Publisher: Cambridge University PressPrint publication year: 2020